Vilanterol
Asthma drug – β2 adrenoreceptor agonist
- EU EMA: by INN
category
- AU: B3
- R03AK10 (WHO) (+fluticasone)
R03AL03 (WHO) (+umeclidinium)
- AU: S4 (Prescription only)
- UK: POM (Prescription only)
- US: ℞-only
- In general: ℞ (Prescription only)
- 4-{(1R)-2-[(6-{2-[(2,6-Dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol
- 503068-34-6
- 10184665
- 7353
- 8360167
- 028LZY775B
- D09696
- CHEBI:75037
- ChEMBL1198857
- DTXSID80198318
- Interactive image
- c1cc(c(c(c1)Cl)COCCOCCCCCCNC[C@@H](c2ccc(c(c2)CO)O)O)Cl
- InChI=1S/C24H33Cl2NO5/c25-21-6-5-7-22(26)20(21)17-32-13-12-31-11-4-2-1-3-10-27-15-24(30)18-8-9-23(29)19(14-18)16-28/h5-9,14,24,27-30H,1-4,10-13,15-17H2/t24-/m0/s1
- Key:DAFYYTQWSAWIGS-DEOSSOPVSA-N
Vilanterol (INN, USAN) is an ultra-long-acting β2 adrenoreceptor agonist (ultra-LABA), which was approved in May 2013 in combination with fluticasone furoate for sale as Breo Ellipta by GlaxoSmithKline for the treatment of chronic obstructive pulmonary disease (COPD).[1][2]. The combination is also approved for the treatment of asthma in Canada, Europe, Japan[3] and New Zealand.[4]
Vilanterol is available in following combinations:
- with inhaled corticosteroid fluticasone furoate—fluticasone furoate/vilanterol (trade names Breo Ellipta (U.S., NZ), Relvar Ellipta (EU, RU, JPN))
- with muscarinic antagonist umeclidinium bromide—umeclidinium bromide/vilanterol (trade name Anoro Ellipta)
- with inhaled corticosteroid fluticasone furoate and muscarinic antagonist umeclidinium bromide—fluticasone furoate/umeclidinium bromide/vilanterol (trade name Trelegy Ellipta)
See also
- Salmeterol—the long-acting β2 adrenoreceptor agonist (LABA) from which vilanterol was derived.
References
- ^ "FDA approves Breo Ellipta to treat chronic obstructive pulmonary disease". Food and Drug Administration. Retrieved 10 May 2013.
- ^ McKeage K (September 2014). "Fluticasone furoate/vilanterol: a review of its use in chronic obstructive pulmonary disease". Drugs. 74 (13): 1509–22. doi:10.1007/s40265-014-0269-6. PMID 25074268. S2CID 29379731.
- ^ Syed YY (March 2015). "Fluticasone furoate/vilanterol: a review of its use in patients with asthma". Drugs. 75 (4): 407–18. doi:10.1007/s40265-015-0354-5. PMID 25648266. S2CID 24563680.
- ^ Zealand (www.bka.co.nz), Site designed and developed by bka interactive ltd, Auckland, New (22 June 2019). "Fluticasone and vilanterol | Health Navigator NZ". Health Navigator New Zealand.
{{cite web}}
: CS1 maint: multiple names: authors list (link)
- v
- t
- e
Short-acting β2 agonists | |
---|---|
Long-acting β2 agonists |
|
Ultra-long-acting β2 agonists |
|
Other |
muscarinic antagonist
Leukotriene antagonists | |
---|---|
Arachidonate 5-lipoxygenase inhibitors | |
Thromboxane receptor antagonists | |
Non-xanthine PDE4 inhibitors |
- Aclidinium bromide/formoterol
- Beclometasone/formoterol
- Beclometasone/formoterol/glycopyrronium bromide
- Budesonide/formoterol
- Budesonide/glycopyrronium bromide/formoterol
- Fluticasone furoate/umeclidinium bromide/vilanterol
- Fluticasone furoate/vilanterol
- Fluticasone propionate/salmeterol
- Glycopyrronium bromide/formoterol
- Indacaterol/glycopyrronium bromide
- Indacaterol/glycopyrronium bromide/mometasone
- Indacaterol/mometasone
- Ipratropium bromide/salbutamol
- Mometasone/formoterol
- Salbutamol (albuterol)/budesonide
- Theophylline/ephedrine
- Theophylline/ephedrine/hydroxyzine
- Theophylline/ephedrine/phenobarbital
- Umeclidinium bromide/vilanterol
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
This drug article relating to the respiratory system is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e